methyl N-(2,6-dichlorobenzoyl)-L-tyrosinate | 938195-80-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-(2,6-dichlorobenzoyl)-L-tyrosinate
• 英文别名: methyl (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-(4-hydroxyphenyl)propanoate
• CAS: 938195-80-3
• 化学式: C₁₇H₁₅Cl₂NO₄
• 分子量: 368.216
• InChiKey: XGPOCIJTUIZGEM-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl N-(2,6-dichlorobenzoyl)-L-tyrosinate 在 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以40%的产率得到methyl N-(2,6-dichlorobenzoyl)-3-fluoro-L-tyrosinate
  参考文献：
  名称：

  WO2007/141473

  摘要：

  公开号：
• 作为产物：
  描述：

  2,6-二氯苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.5h， 以83%的产率得到methyl N-(2,6-dichlorobenzoyl)-L-tyrosinate
  参考文献：
  名称：

  WO2007/60408

  摘要：

  公开号：

文献信息

• [EN] N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS D'ACIDES AMINÉS N-ACYLE ET MÉTHODES D'UTILISATION
  申请人：PLIANT THERAPEUTICS INC

  公开号：WO2018049068A1

  公开（公告）日：2018-03-15

  The invention relates to compounds of formula (I), or a salt thereof wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ανβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.

  该发明涉及式(I)的化合物或其盐，其中R1、A、L、R2和n如本文所述。式(I)的化合物及其药物组成物是ανβ1整合素抑制剂，可用于治疗特定组织纤维化。
• Rh-catalyzed aerobic oxidative cyclization of anilines, alkynes, and CO
  作者：Xinyao Li、Jun Pan、Hao Wu、Ning Jiao

  DOI：10.1039/c7sc02181j

  日期：——

  Transition-metal-catalyzed oxidative C-H cyclization of anilines has been an attractive and powerful strategy for the efficient construction of N-heterocycles. However, the primary and tertiary anilines are rarely employed in this strategy due to the relatively unstability with strong oxidants or the presence of three C-N bonds. By using aerobic oxidative protocol, we describe here a novel Rh-catalyzed

  苯胺的过渡金属催化的氧化 CH 环化已成为有效构建 N-杂环的有吸引力且有效的策略。然而，由于与强氧化剂相对不稳定或存在三个CN键，伯苯胺和叔苯胺很少用于该策略。通过使用有氧氧化协议，我们在这里描述了一种新颖的 Rh 催化 CH 环化各种苯胺与炔烃和 CO。特别是，简单的伯苯胺和通过 CN 键裂解容易制备的叔苯胺可以很容易地转化为 quinolin-2 (1H)-ones，它们是高附加值、具有生物学意义的 N-杂环化合物。
• PHENYLALANINE DERIVATIVES
  申请人：Arnould Jean-Claude

  公开号：US20080045521A1

  公开（公告）日：2008-02-21

  The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有其作为活性成分的制药组合物，以及它们作为药物在温血动物（如人类）中治疗具有明显血管生成或血管成分的疾病，例如固体肿瘤的制药用途。本发明还涉及a5b1拮抗剂，其还表现出对其他整合素的适当选择性特征。
• L-Phenylalanine Derivatives
  申请人：Barry Simon Thomas

  公开号：US20090137601A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，以及包含其作为活性成分的制药组合物，以及它们作为药物在温血动物（如人类）中治疗具有显著血管生成或血管成分的疾病，如实体肿瘤的制剂中的用途。本发明还涉及抑制a5b1的化合物，以及对其他整合素具有适当选择性谱的化合物。
• CHEMICAL COMPOUNDS
  申请人：Arnould Jean Claude

  公开号：US20090203663A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及抑制a5b1功能的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗具有显著血管生成或血管成分的疾病的药物中的使用，如用于治疗实体肿瘤等温血动物（如人类）。本发明还涉及抑制a5b1的化合物，以及对其他整合素具有适当选择性特征的化合物。